

**Iowa Medicaid Pharmaceutical and Therapeutics Committee  
Minutes**

**Date:** April 17, 2014

**Chairperson:** Charles Wadle, D.O.

**Time:** 9:35 a.m. to 12:01 p.m.

**Location:** Learning Resource Center, Community Room, West Des Moines, Iowa

**Committee Members Present:** Charles Wadle, D.O.; Carole Frier, D.O.; Bruce Alexander, Pharm.D.; Jolene Kelly, PA-C; Stephen Richards, D.O.; Linda Gehrke, ARNP; Holly Randleman, Pharm.D.; and Heidi Price-Eastman, R.Ph.

**Iowa DHS Staff Present:** Susan Parker, Pharm.D., Pharmacy Consultant

**Iowa Medicaid Enterprise (IME) Staff Present:** Steve Liles, Pharm.D.; Lauren Biczak, D.O.; Erin Halverson, R.Ph.; Megan Smith, Pharm.D.; Pam Smith, R.Ph.; and Melissa Biddle.

Chairperson Charles Wadle called the meeting to order.

- I. Chuck Wadle asked that each committee, DHS staff, and IME staff member introduce themselves to the public. The November 21, 2013, open session minutes were reviewed. Linda Gehrke made the motion to approve the minutes. Bruce Alexander seconded the motion. The motion passed with no objections.
- II. PDL and Drug Rebate Issues (Dr. Liles): Pharmacy spending has been down the last couple of years, but is expected to increase by 2-4% per year over the next 4 years. By 2017, the Oncology category will be the most expensive, with more than twice the expenditures of the second place Diabetes class. Specialty drug spending will be increasing by 20-30%. The CMS final rules with regards to the Healthcare Reform Act, including information on line extension drugs and FUL pricing, have still not been released.
- III. PA Criteria/Pro-DUR Edits/Legislation (Dr.Parker): Informational Letter 1323 notified providers about the preferred lancet and syringe manufacturers, and the corresponding products and their NDC numbers, effective January 1, 2014. Informational Letter 1325 listed the PDL changes that had been voted on at the November P&T meeting, along with new prior authorization (PA) criteria for Xarelto and testosterone products and modified criteria for pre-filled insulin pens. Informational Letter 1338 clarified the registration process for the new Iowa Medicaid Pharmacy Provider Portal and its features. Informational Letter 1339 provided important dates with regards to the 2014 cost of dispensing fee survey. Informational Letter 1344 detailed billing and adjustment of 340B claims. Informational Letter 1361 outlined new PA criteria for Eliquis, along with changes to the criteria for: Hepatitis C Protease Inhibitors, Proton Pump Inhibitors, and Xyrem. Additionally, providers received a fax notification on January 30, 2014, which pertained to prescription combination products containing more than 325mg of acetaminophen; Iowa Medicaid removed coverage of these products effective

February 7, 2014. The committee also received copies of three letters sent to the Department of Human Services from the Drug Utilization Review Commission, which included recommended criteria for Hepatitis C Protease Inhibitors, Eliquis, Xyrem, Proton Pump Inhibitors, Non-Insulin Anti-Diabetic Agents, and Mekinist, as well as suggested quantity limits for butalbital containing products and transdermal scopolamine. In legislative news, the appropriations bill is still pending approval in the Iowa Senate, having passed in the House already.

IV. The public speakers were:

Name	Representing	Drug/Topic
Douglas Hornick, M.D.	University of Iowa Adult Cystic Fibrosis Center	Inhaled antibiotics for Cystic Fibrosis
Bart Brown, Pharm.D.	Eisai	Fycompa
Rachel Anhorn, Pharm.D.	Boehringer-Ingelheim	Lung cancer, Gilotrif
Tari Malmgren, Pharm.D.	Actelion	Opsumit
Peter Calabuono	Silvergate	Epaned
Kathleen Karnik	Johnson & Johnson	Olysio
Chad Patel	Bristol-Myers Squibb	Eliquis
Joe Llewellyn	Gilead	Sovaldi

At 10:38, motion to go to closed session was made by Stephen Richards and seconded by Jolene Kelly and Bruce Alexander simultaneously. The motion passed with unanimous approval. Open session resumed at 11:47.

- V. PDL Discussion and Deliberation (Dr. Biczak): All following recommendations were made to maximize cost savings to the program unless otherwise noted. Cyproheptadine will change to non-preferred. The following will all be non-preferred with conditions: fenoprofen, ketoprofen er, oxaprozin, Ritalin, and Ritalin SR. Paroxetine er will change to preferred, and methylphenidate er 20mg tablets will change to preferred with conditions. Bruce Alexander motioned to accept the above recommendations, and Linda Gehrke seconded. The decision was unanimous.
- VI. Newly Released Drugs (Dr. Biczak): All following recommendations were made to maximize cost savings to the program unless otherwise noted. Adempas, Olysio, and Opsumit were all recommended to be non-preferred with conditions. Brintellix, Fetzima, and Fycompa will be non-preferred. Gilotrif will be non-recommended, and Sovaldi will be preferred with conditions, requiring prior authorization to document that the clinical circumstances are appropriate for this therapy. Jolene Kelly motioned to accept the above recommendations, and Linda Gehrke seconded. The decision was unanimous.
- VII. Newly Released Generic Drugs, New Dosage Forms/Strengths (Dr. Biczak): All following recommendations were made to maximize cost savings to the program unless otherwise noted. These medications will all be non-preferred: diclofenac 3% gel, fluocinonide 0.1% cream, gatifloxacin, niacin er, paricalcitol, tobramycin nebulization solution, tolterodine er, Epaned, Procsybi, and Versacloz. Abacavir/lamivudine/zidovudine, mycophenolic acid, sirolimus, and Rixubis will all be non-recommended. The following will be non-preferred with conditions:

clonidine er, dexmethylphenidate er, duloxetine, lidocaine patch, rabeprazole, telmisartan, telmisartan/amlodipine, Khedezla ER, Trokendi XR, and Zorvolex. Bethkis will be preferred. Stephen Richards motioned to accept the above recommendations. Heidi Price-Eastman seconded the motion, and all members were in favor.

A motion was made by Holly Randleman to adjourn the meeting. Heidi Price-Eastman seconded the motion. All in attendance approved. The meeting adjourned at 12:01 p.m. The next scheduled meeting is tentatively set for August 21, 2014.